Answers are grounded in this paper and cite their sources.
Iptacopan is an orally administered proximal complement inhibitor targeting factor B to selectively inhibit the alternative pathway of the complement system, while sparing activity of the classical pathway. Previous studies have shown that iptacopan is rapidly absorbed, reaching maximum concentration in approximately 1–2 h, and that dose–exposure proportionality is achieved after multiple doses of 100 mg and 200 mg twice daily (BID). The approved clinical dose is 200 mg BID. This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple supratherapeutic doses of iptacopan (400 and 800 mg BID) in healthy adult participants. The trial was a randomized, placebo-controlled, double-blinded phase 1 multiple-ascending-dose study conducted in two sequential cohorts. A total of 26 participants were randomized 2:1 to BID iptacopan 400 mg or 800 mg for 14 days or matching placebo; 24 participants completed the study. Treatment-emergent adverse events (TEAEs) were mild to moderate, and there were no serious AEs, deaths, or discontinuations due to AEs. The most frequent TEAE was headache, occurring in five (20.8%) participants. Plasma measures of iptacopan exposure appeared to increase in a dose-proportional manner, and biomarker analyses showed that there was rapid, near-complete, and persistent inhibition of alternative pathway activity for both doses, measured by the Wieslab assay. These findings show that iptacopan supratherapeutic doses of 400 mg and 800 mg BID are well tolerated in healthy participants and describe the PK and PD properties of iptacopan and inhibition of the alternative complement pathway.
No takes yet. Share an insight, caveat, or question.
Kulmatycki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: